98%
921
2 minutes
20
Background: Non‑alcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation and is closely associated with inflammation and metabolic dysregulation. The C‑reactive protein-albumin-lymphocyte (CALLY) index, a composite marker of inflammation, immunity, and nutritional status, remains understudied in relation to NAFLD.
Methods: A crosssectional analysis was conducted using data from 7,271 U.S. adults in NHANES 2017-2020. NAFLD was defined by vibrationcontrolled transient elastography with a controlled attenuation parameter (CAP) > 274 dB/m. Weighted logistic regression, restricted cubic spline (RCS) modeling, and twopiecewise logistic regression were applied to assess linear and nonlinear associations between the CALLY index and NAFLD prevalence. Subgroup and sensitivity analyses were performed to evaluate the consistency and robustness of the findings.
Results: The mean CALLY index was 8.08 (SD 12.42). Higher CALLY levels were inversely associated with NAFLD prevalence ( OR = 0.96; 95% CI, 0.95-0.98). Compared with the lowest quartile (Q1 < 1.90), the highest quartile (Q4 > 10.00) showed a 61% lower prevalence of NAFLD (OR = 0.39; 95% CI, 0.24-0.64). RCS analysis demonstrated a significant nonlinear relationship, with a threshold at 8.91; below this value, each unit increase in the CALLY index corresponded to a 10% reduction in NAFLD prevalence (OR = 0.90; 95% CI, 0.88-0.92). Subgroup and sensitivity analyses yielded consistent results, confirming the robustness of these findings.
Conclusion: The CALLY index demonstrates a significant inverse association with NAFLD prevalence and may serve as a simple composite indicator for identifying individuals at higher likelihood of NAFLD, providing additional insights to inform future screening and risk‑stratification research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12395825 | PMC |
http://dx.doi.org/10.1186/s13098-025-01926-y | DOI Listing |
Lipids Health Dis
September 2025
Epidemiology, Medical Faculty, University of Augsburg, Stenglingstr. 2, Augsburg, 86156, Germany.
Background: This study aimed to investigate the gender-specific associations of skeletal muscle mass and fat mass with non-alcoholic fatty liver disease (NAFLD) and NAFLD-related liver fibrosis in two population-based studies.
Methods: Analyses were based on data from the MEGA (n = 238) and the MEIA study (n = 594) conducted between 2018 and 2023 in Augsburg, Germany. Bioelectrical impedance analysis was used to evaluate relative skeletal muscle mass (rSM) and SM index (SMI) as well as relative fat mass (rFM) and FM index (FMI); furthermore, the fat-to-muscle ratio was built.
Nutr Metab Cardiovasc Dis
July 2025
Department of Gastroenterology, The Affiliated People's Hospital of Ningbo University, Ningbo, 315040, PR China. Electronic address:
Background And Aims: Obesity-related non-alcoholic fatty liver disease (NAFLD) and serum high-sensitivity C-reactive protein (hs-CRP) are known to be associated to some extent. Nevertheless, this relationship remains unclear in non-obese individuals.
Methods And Results: A prospective cohort study was conducted using data from the health check ups of employees at Zhenhai Refining and Chemical Hospital in Ningbo City.
Gen Physiol Biophys
September 2025
Department of Endocrinology and Metabolism, Central People's Hospital of Zhanjiang, Zhanjiang City, Guangdong Province, China.
This study explores how human antigen R (HuR) stabilizes fibroblast growth factor 19 (FGF19) mRNA, inhibiting Kupffer cell (KC) activation to reduce inflammation and fibrosis in non-alcoholic fatty liver disease (NAFLD). An animal model of NAFLD was established in mice by administering a high-fat diet (HFD). In vitro study utilized a lipopolysaccharide-induced immortalized mouse KC model.
View Article and Find Full Text PDFLiver Int
October 2025
The Global NASH Council, Washington, DC, USA.
Background: The Middle East and North Africa (MENA) region is undergoing demographic shifts potentially increasing metabolic dysfunction-associated steatotic liver disease (MASLD) and its complications. We assessed MASLD prevalence and liver disease burden from 2010 to 2021.
Methods: Data from Global Burden of Disease (GBD), United Nations Population Division and NCD Risk Factor Collaboration covering 21 MENA countries were used for annual percent change (APC) trends per Joinpoint regression.
Diabetes Obes Metab
September 2025
Phase I Clinical Trial Research Ward, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, People's Republic of China.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern, and its presence increases the risk of multi-system diseases. This study aimed to investigate the multimorbidity trajectories of chronic diseases in people living with MASLD.
Methods: We identified 137 859 MASLD patients in UK Biobank and used 'propensity score matching' to match an equal number of non-MASLD controls.